Indoco Remedies (INDOCO) Aktienübersicht
Indoco Remedies Limited produziert, vermarktet und verkauft Formulierungen und aktive pharmazeutische Inhaltsstoffe in Indien und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 1/6 |
| Finanzielle Gesundheit | 2/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
INDOCO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Indoco Remedies Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹226.29 |
| 52-Wochen-Hoch | ₹332.20 |
| 52-Wochen-Tief | ₹162.19 |
| Beta | 0.62 |
| 1 Monat Veränderung | -2.96% |
| 3 Monate Veränderung | 13.67% |
| 1 Jahr Veränderung | -19.05% |
| 3 Jahre Veränderung | -30.08% |
| 5 Jahre Veränderung | -49.71% |
| Veränderung seit IPO | 330.48% |
Aktuelle Nachrichten und Updates
Here's What Analysts Are Forecasting For Indoco Remedies Limited (NSE:INDOCO) After Its First-Quarter Results
Indoco Remedies Limited ( NSE:INDOCO ) shareholders are probably feeling a little disappointed, since its shares fell...
INDOCO: Ophthalmic Transfer And EU Approvals Will Shape Balanced Stock Outlook
Analysts have kept the Indoco Remedies price target steady at ₹250, citing small model tweaks to revenue growth, profit margin, and assumed future P/E that offset one another in their valuation work. What’s in the News for Indoco Remedies Indoco Remedies received EU GMP certification from the German Health Authority, Berlin, for its Oral Solid Dosage manufacturing facility, Plant III at Baddi, following an inspection conducted from April 22, 2026 to April 27, 2026.Recent updates
Here's What Analysts Are Forecasting For Indoco Remedies Limited (NSE:INDOCO) After Its First-Quarter Results
Indoco Remedies Limited ( NSE:INDOCO ) shareholders are probably feeling a little disappointed, since its shares fell...INDOCO: Ophthalmic Transfer And EU Approvals Will Shape Balanced Stock Outlook
Analysts have kept the Indoco Remedies price target steady at ₹250, citing small model tweaks to revenue growth, profit margin, and assumed future P/E that offset one another in their valuation work. What’s in the News for Indoco Remedies Indoco Remedies received EU GMP certification from the German Health Authority, Berlin, for its Oral Solid Dosage manufacturing facility, Plant III at Baddi, following an inspection conducted from April 22, 2026 to April 27, 2026.INDOCO: Ophthalmic Business Transfer Will Shape Bullish Outlook
Analysts have kept the fair value for Indoco Remedies steady at ₹250, as small adjustments to revenue growth, profit margin, and future P/E assumptions offset each other rather than pointing to a clear shift in the stock's valuation story. What's in the News The Malta Medicines Authority inspected Indoco Remedies' solid oral dosage facility at Baddi (Unit I) from January 29, 2026 to February 3, 2026 and granted EU GMP certification confirming compliance with Good Manufacturing Practice requirements under the EC Directive.The Indoco Remedies Limited (NSE:INDOCO) Annual Results Are Out And Analysts Have Published New Forecasts
Investors in Indoco Remedies Limited ( NSE:INDOCO ) had a good week, as its shares rose 8.8% to close at ₹228 following...INDOCO: Ophthalmic Business Transfer And ANDA Approval Will Shape Balanced Outlook
Analysts have raised their price target on Indoco Remedies from ₹207 to ₹250, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E ratio that together suggest a higher estimated fair value for the stock. What's in the News A board meeting is scheduled for April 30, 2026, to consider transferring Indoco Remedies' ophthalmic business in India and agreed territories in Africa to Sunways (India) Private Limited, on terms set out in a business transfer agreement (Key Developments).Here's Why Shareholders Should Examine Indoco Remedies Limited's (NSE:INDOCO) CEO Compensation Package More Closely
Key Insights Indoco Remedies will host its Annual General Meeting on 11th of September Total pay for CEO Sundeep...Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259
Indoco Remedies Limited ( NSE:INDOCO ) last week reported its latest quarterly results, which makes it a good time for...Indoco Remedies Limited (NSE:INDOCO) Soars 27% But It's A Story Of Risk Vs Reward
The Indoco Remedies Limited ( NSE:INDOCO ) share price has done very well over the last month, posting an excellent...Revenues Working Against Indoco Remedies Limited's (NSE:INDOCO) Share Price Following 25% Dive
Indoco Remedies Limited ( NSE:INDOCO ) shares have had a horrible month, losing 25% after a relatively good period...
Plant Remediation And Clarity Pharma Partnership Will Support Future Market Expansion
Resolving manufacturing plant issues is critical for increasing U.S. market supply, boosting revenue, and minimizing compliance risks.₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results
There's been a notable change in appetite for Indoco Remedies Limited ( NSE:INDOCO ) shares in the week since its...Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
It's been a mediocre week for Indoco Remedies Limited ( NSE:INDOCO ) shareholders, with the stock dropping 11% to ₹304...Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders
A lackluster earnings announcement from Indoco Remedies Limited ( NSE:INDOCO ) last week didn't sink the stock price...Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts
It's shaping up to be a tough period for Indoco Remedies Limited ( NSE:INDOCO ), which a week ago released some...Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now
Performance at Indoco Remedies Limited ( NSE:INDOCO ) has been reasonably good and CEO Sundeep Bambolkar has done a...Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Indoco Remedies Limited ( NSE:INDOCO ) has announced that it will be increasing its dividend on the 23rd of October to...Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Indoco Remedies Limited ( NSE:INDOCO ) has announced that it will be increasing its dividend on the 23rd of October to...Aktionärsrenditen
| INDOCO | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | 3.1% | -0.7% | -0.5% |
| 1Y | -19.1% | 15.2% | 1.7% |
Rendite im Vergleich zur Industrie: INDOCO unter dem Niveau der Branche Indian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 15.2% erzielte.
Rendite vs. Markt: INDOCO hinter dem Markt Indian zurück, der im vergangenen Jahr eine Rendite von 1.7 erzielte.
Preisvolatilität
| INDOCO volatility | |
|---|---|
| INDOCO Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Stabiler Aktienkurs: Der Aktienkurs von INDOCO war in den letzten 3 Monaten im Vergleich zum Indian -Markt volatil.
Volatilität im Zeitverlauf: INDOCODie wöchentliche Volatilität (7%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der Indian Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1945 | 6,000 | Sundeep Bambolkar | www.indoco.com |
Indoco Remedies Limited produziert, vermarktet und verkauft Formulierungen und pharmazeutische Wirkstoffe in Indien und international. Das Unternehmen bietet stomatologische, gastrointestinale, respiratorische, Antiinfektiva, Vitamine/Mineralien/Nährstoffe, ophthalmologische/ontologische, dermatologische, urologische, antidiabetische, gynäkologische, Lifestyle-Management-, Schmerz-/Analgetika- und Herzprodukte. Das Unternehmen bietet auch Markengenerika an, darunter Schmerztabletten und topische Präparate, blutdrucksenkende Mittel, Protein-Nahrungsergänzungsmittel, Multivitamin-Tabletten und -Sirupe, Antibiotika-Tabletten, -Sirupe und -Injektionspräparate, orale Rehydrierungspulver, Antazida und Antihistaminika sowie Hämorrhoidalcremes und Kalziumpräparate.
Indoco Remedies Limited's Grundlagenzusammenfassung
| INDOCO grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹20.55b |
| Gewinn(TTM) | ₹56.30m |
| Umsatz(TTM) | ₹18.73b |
Ist INDOCO zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| INDOCO Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹18.73b |
| Kosten der Einnahmen | ₹5.65b |
| Bruttogewinn | ₹13.08b |
| Sonstige Ausgaben | ₹13.03b |
| Gewinn | ₹56.30m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 0.61 |
| Bruttomarge | 69.85% |
| Nettogewinnspanne | 0.30% |
| Schulden/Eigenkapital-Verhältnis | 116.9% |
Wie hat sich INDOCO auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/21 11:39 |
| Aktienkurs zum Tagesende | 2026/08/21 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Indoco Remedies Limited wird von 14 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| Srivathsan Ramachandran | Avendus Spark |